News
Press Releases
November 4, 2021
NodThera Announces Progress of NT-0796, a Novel NLRP3 Inflammasome Inhibitor, into a Phase 1 First-in-Human Study
-Study of lead candidate to provide important information on safety, pharmacokinetics and pharmacodynamics to inform further clinical…
December 15, 2020
NodThera Appoints Chief Medical Officer and Chief Financial Officer
Strengthens senior leadership team with appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton,…
June 3, 2020
NodThera Announces Close of $55 Million Series B Financing
Financing round led by Novo Holdings and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as…
November 4, 2021
NodThera Announces Progress of NT-0796, a Novel NLRP3 Inflammasome Inhibitor, into a Phase 1 First-in-Human Study
-Study of lead candidate to provide important information on safety, pharmacokinetics and pharmacodynamics to inform further clinical…
December 15, 2020
NodThera Appoints Chief Medical Officer and Chief Financial Officer
Strengthens senior leadership team with appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton,…
June 3, 2020
NodThera Announces Close of $55 Million Series B Financing
Financing round led by Novo Holdings and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as…
April 10, 2019
NodThera Highlights Significant Progress with Advancement of Lead Development Candidate and Key Additions to Board
– Company advances NT-0167 as first development candidate from a broad platform of NLRP3 inflammasome inhibitors –…
October 23, 2018
NodThera announces the appointment of Alison Strutt PhD as Head of Finance & Operations, the launch of its new corporate office in Boston and the opening of its laboratory in Seattle
– Expansion in the US is consistent with NodThera’s strategy to access world class talent, foster collaborative…
September 23, 2018
NodThera announces the appointment of Adam Keeney PhD as President and Chief Executive Officer
– Dr Keeney joins NodThera with over 20 years of pharmaceutical industry experience, including most recently at…
June 25, 2018
NodThera secures £28 million ($40 million) Series A Financing
– NodThera discovers and develops next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by…
July 28, 2016
Epidarex Capital Creates Nodthera Limited
A pioneering new company based on Selvita research and utilizing novel immunological approaches to disease Edinburgh, Scotland,…
Media Contact
Darby Pearson
Verge Scientific Communications
dpearson@vergescientific.com
For all other company inquiries, contact us at info@nodthera.com.
